Outcome heterogeneity of
TP53
-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation
Haematologica
.
2024 Mar 1;109(3):948-952.
doi: 10.3324/haematol.2023.283886.
Authors
Sergiu Pasca
1
,
Saurav D Haldar
1
,
Alexander Ambinder
1
,
Jonathan A Webster
1
,
Tania Jain
1
,
W Brian Dalton
1
,
Gabrielle T Prince
1
,
Gabriel Ghiaur
1
,
Amy E DeZern
1
,
Ivana Gojo
1
,
B Douglas Smith
1
,
Theodoros Karantanos
1
,
Cory Schulz
1
,
Kristin Stokvis
1
,
Mark J Levis
1
,
Richard J Jones
1
,
Lukasz P Gondek
2
Affiliations
1
Division of Hematological Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University.
2
Division of Hematological Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University. lgondek1@jhmi.edu.
PMID:
37731390
PMCID:
PMC10905097
DOI:
10.3324/haematol.2023.283886
No abstract available
Publication types
Letter
MeSH terms
Hematopoietic Stem Cell Transplantation*
Humans
Neoplasms*
Tumor Suppressor Protein p53 / genetics
Substances
TP53 protein, human
Tumor Suppressor Protein p53
Grants and funding
R01 HL156144/HL/NHLBI NIH HHS/United States